BRAF and non-small cell lung carcinoma: Notably, treatment with a BRAF inhibitor, such as vemurafenib or dabrafenib, has achieved an objective response rate (ORR) of 33–42% and median progression-free survival (PFS) of 5.5 to 7.3 months in V600E BRAF-mutated NSCLC patients, respectively [9, 10].